The invention of a unique combination stem cell therapy represents a substantial promise as a cellular agent for cardiac diseases as well as circulatory problem affecting the legs. The protocols have been released by the FDA to begin Phase I research studies in these two fields. This gives our company a leading edge in the regenerative medicine field.

The use of single or combination stem cell therapy may also be applied to other devastating diseases that we developing to cure.

Our clinical trials use autologous adult stem cell therapy. This means that a subject uses his/her own stem cells for the therapy and not someone else’s.

Ongoing Clinical Trials

Current Phase I and Phase II clinical trials, being conducted using autologous bone marrow (BM)-derived stem cells have been designed for:

1. Phase I: Repair of infarcted myocardium (heart attack) in patients during bypass surgery.
2. Phase I: Rescue and repair of cardiac muscle after acute myocardial infarction (heart attack).
3. Phase I: Severe coronary ischemia (blockages to the heart).
4. Phase II: Treatment of severe limb ischemia (blockages in the leg).

Clinical Trials Submitted to the FDA pending review:

1. Phase II: Severe Coronary Ischemia (blockages to the heart).
2. Phase I: ALS (Lou Gehrig's Disease).

Future Directions

Future Directions: TCA Cellular Therapy is designing protocols to treat neurological diseases such as spinal cord injuries, Parkinson’s and ALS.

TCA Cellular Therapy is currently seeking approval from the FDA to utilize stem cells in the treatment of Amyotrophic Lateral Sclerosis (Lou Gehrig's disease). The company is also anticipating new uses for other cardiac diseases such as idiopathic cardiomyopathy.

TCA Cellular Therapy is also interested in designing protocols for other indications such as Parkinson's Disease and spinal injuries. The company is also anticipating new uses for other cardiac diseases such as idiopathic cardiomyopathy.

Current Phase I clinical trials, being conducted using autologous bone marrow (BM)-derived stem cells have been designed for:

1. Repair of infarcted myocardium in patients during bypass surgery.
2. Rescue and repair of cardiac muscle after acute myocardial infarction.
3. Treatment of severe limb ischemia

To review our clinical trials, please click here.

Back to Top